International Clinical Trial: SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07725705) titled 'SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)' on July 21.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Condition: PTCL First Line Treatment

Intervention: Drug: SHR2554 combined with Liposomal Mitoxantrone

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: August 1, 2026

Target Sample Size: 44

To know more, visit https://clinicaltrials...